Ionis Pharmaceuticals Stock EBITDA

IONS Stock

USD 33.94 1.46 4.12%

Ionis Pharmaceuticals fundamentals help investors to digest information that contributes to Ionis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ionis Stock. The fundamental analysis module provides a way to measure Ionis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ionis Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	EBITDA	-230 M	-218.5 M

EBITDA is likely to gain to about (218.5 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Ionis Pharmaceuticals Company EBITDA Analysis

Ionis Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Ionis Pharmaceuticals EBITDA

(230.01 M)

Most of Ionis Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ionis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Ionis EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Ionis Pharmaceuticals is extremely important. It helps to project a fair market value of Ionis Stock properly, considering its historical fundamentals such as EBITDA. Since Ionis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ionis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ionis Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Net Receivables	Short Term Investments	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.73	-0.16	-0.6	0.93	1.0	0.3	0.74	0.52	0.5	0.96	0.43	0.86	0.52	0.91	0.83	0.86	0.93	0.0	0.28	0.94	0.95	0.61	-0.48
Total Stockholder Equity	0.73		-0.75	-0.04	0.43	0.7	0.24	0.5	0.18	0.09	0.67	0.32	0.35	0.74	0.57	0.96	0.33	0.76	-0.1	0.24	0.79	0.74	0.01	0.15
Net Debt	-0.16	-0.75		-0.38	0.17	-0.14	-0.09	-0.11	0.09	0.3	-0.1	-0.13	0.17	-0.63	-0.03	-0.57	0.22	-0.27	0.03	-0.12	-0.29	-0.17	0.54	-0.7
Retained Earnings	-0.6	-0.04	-0.38		-0.78	-0.62	-0.27	-0.8	-0.7	-0.47	-0.54	-0.71	-0.74	-0.22	-0.63	-0.1	-0.78	-0.54	-0.27	-0.25	-0.36	-0.42	-0.61	0.59
Total Liab	0.93	0.43	0.17	-0.78		0.94	0.29	0.73	0.58	0.61	0.9	0.4	0.95	0.31	0.88	0.58	0.96	0.84	0.05	0.27	0.82	0.86	0.78	-0.68
Total Current Assets	1.0	0.7	-0.14	-0.62	0.94		0.32	0.75	0.52	0.53	0.95	0.42	0.87	0.52	0.9	0.81	0.87	0.93	0.01	0.3	0.93	0.94	0.63	-0.49
Short Term Debt	0.3	0.24	-0.09	-0.27	0.29	0.32		0.29	0.1	0.33	0.33	0.11	0.07	0.46	0.28	0.26	0.08	0.39	-0.06	1.0	0.27	0.17	0.18	-0.13
Intangible Assets	0.74	0.5	-0.11	-0.8	0.73	0.75	0.29		0.52	0.29	0.64	0.81	0.69	0.59	0.64	0.48	0.71	0.75	0.13	0.28	0.6	0.62	0.33	-0.24
Accounts Payable	0.52	0.18	0.09	-0.7	0.58	0.52	0.1	0.52		0.33	0.47	0.56	0.48	0.19	0.72	0.21	0.52	0.47	0.4	0.09	0.24	0.31	0.36	-0.42
Net Receivables	0.5	0.09	0.3	-0.47	0.61	0.53	0.33	0.29	0.33		0.48	0.04	0.56	0.19	0.5	0.24	0.57	0.47	-0.07	0.32	0.43	0.44	0.56	-0.55
Short Term Investments	0.96	0.67	-0.1	-0.54	0.9	0.95	0.33	0.64	0.47	0.48		0.29	0.81	0.42	0.92	0.79	0.81	0.91	-0.2	0.32	0.9	0.92	0.62	-0.5
Common Stock	0.43	0.32	-0.13	-0.71	0.4	0.42	0.11	0.81	0.56	0.04	0.29		0.36	0.55	0.39	0.21	0.4	0.37	0.28	0.1	0.24	0.24	0.14	-0.1
Long Term Debt	0.86	0.35	0.17	-0.74	0.95	0.87	0.07	0.69	0.48	0.56	0.81	0.36		0.26	0.76	0.48	1.0	0.76	0.02	0.05	0.78	0.82	0.72	-0.59
Property Plant Equipment	0.52	0.74	-0.63	-0.22	0.31	0.52	0.46	0.59	0.19	0.19	0.42	0.55	0.26		0.42	0.62	0.25	0.56	-0.09	0.46	0.54	0.43	-0.08	0.21
Current Deferred Revenue	0.91	0.57	-0.03	-0.63	0.88	0.9	0.28	0.64	0.72	0.5	0.92	0.39	0.76	0.42		0.7	0.77	0.84	0.03	0.26	0.75	0.8	0.6	-0.57
Net Tangible Assets	0.83	0.96	-0.57	-0.1	0.58	0.81	0.26	0.48	0.21	0.24	0.79	0.21	0.48	0.62	0.7		0.46	0.83	-0.12	0.26	0.88	0.86	0.21	-0.08
Long Term Debt Total	0.86	0.33	0.22	-0.78	0.96	0.87	0.08	0.71	0.52	0.57	0.81	0.4	1.0	0.25	0.77	0.46		0.76	0.04	0.06	0.76	0.81	0.76	-0.64
Capital Surpluse	0.93	0.76	-0.27	-0.54	0.84	0.93	0.39	0.75	0.47	0.47	0.91	0.37	0.76	0.56	0.84	0.83	0.76		-0.03	0.38	0.87	0.89	0.37	-0.25
Deferred Long Term Liab	0.0	-0.1	0.03	-0.27	0.05	0.01	-0.06	0.13	0.4	-0.07	-0.2	0.28	0.02	-0.09	0.03	-0.12	0.04	-0.03		-0.07	-0.16	-0.15	0.06	-0.11
Short Long Term Debt	0.28	0.24	-0.12	-0.25	0.27	0.3	1.0	0.28	0.09	0.32	0.32	0.1	0.05	0.46	0.26	0.26	0.06	0.38	-0.07		0.25	0.15	0.14	-0.08
Net Invested Capital	0.94	0.79	-0.29	-0.36	0.82	0.93	0.27	0.6	0.24	0.43	0.9	0.24	0.78	0.54	0.75	0.88	0.76	0.87	-0.16	0.25		0.97	0.54	-0.35
Net Working Capital	0.95	0.74	-0.17	-0.42	0.86	0.94	0.17	0.62	0.31	0.44	0.92	0.24	0.82	0.43	0.8	0.86	0.81	0.89	-0.15	0.15	0.97		0.56	-0.42
Capital Stock	0.61	0.01	0.54	-0.61	0.78	0.63	0.18	0.33	0.36	0.56	0.62	0.14	0.72	-0.08	0.6	0.21	0.76	0.37	0.06	0.14	0.54	0.56		-0.94
Long Term Investments	-0.48	0.15	-0.7	0.59	-0.68	-0.49	-0.13	-0.24	-0.42	-0.55	-0.5	-0.1	-0.59	0.21	-0.57	-0.08	-0.64	-0.25	-0.11	-0.08	-0.35	-0.42	-0.94

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Ionis Pharmaceuticals

Ebitda Over Time

Ionis Ebitda

Ebitda

(218.51 Million)

At this time, Ionis Pharmaceuticals' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Ionis Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (230.01 Million). This is 126.21% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 105.9% higher than that of the company.

Ionis EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ionis Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ionis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ionis Pharmaceuticals by comparing valuation metrics of similar companies.

Ionis Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Ionis Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ionis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ionis Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Ionis Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Ionis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ionis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ionis Pharmaceuticals' value.

		Shares
Pictet Asset Manangement Sa	2024-06-30	2.4 M
Orbimed Advisors, Llc	2024-06-30	2.4 M
Deep Track Capital, Lp	2024-09-30	2.2 M
Clearbridge Advisors, Llc	2024-06-30	2.2 M
Morgan Stanley - Brokerage Accounts	2024-06-30	2 M
Macquarie Group Ltd	2024-06-30	1.9 M
Artisan Partners Limited Partnership	2024-06-30	1.7 M
Bvf Inc	2024-09-30	1.5 M
Charles Schwab Investment Management Inc	2024-09-30	1.4 M
Fmr Inc	2024-09-30	22.5 M
Vanguard Group Inc	2024-09-30	15.1 M

Ionis Fundamentals

	Return On Equity	-0.73
	Return On Asset	-0.0725
	Profit Margin	(0.45) %
	Operating Margin	(1.11) %
	Current Valuation	4.32 B
	Shares Outstanding	157.9 M
	Shares Owned By Insiders	0.76 %
	Shares Owned By Institutions	99.24 %
	Number Of Shares Shorted	10.74 M
	Price To Earning	101.16 X
	Price To Book	8.09 X
	Price To Sales	6.67 X
	Revenue	787.65 M
	Gross Profit	(257.87 M)
	EBITDA	(230.01 M)
	Net Income	(366.29 M)
	Cash And Equivalents	2.04 B
	Cash Per Share	14.36 X
	Total Debt	1.45 B
	Debt To Equity	2.00 %
	Current Ratio	8.18 X
	Book Value Per Share	4.20 X
	Cash Flow From Operations	(307.51 M)
	Short Ratio	7.97 X
	Earnings Per Share	(2.44) X
	Price To Earnings To Growth	25.70 X
	Target Price	61.36
	Number Of Employees	927
	Beta	0.39
	Market Capitalization	5.36 B
	Total Asset	2.99 B
	Retained Earnings	(1.8 B)
	Working Capital	2.19 B
	Current Asset	837 M
	Current Liabilities	148.88 M
	Net Asset	2.99 B

About Ionis Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ionis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ionis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ionis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC